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Abstract 
Introduction: Non-alcoholic fatty liver is one of the most prevalent digestive diseases in the 
world and its prevalence is increasing rapidly. The objective of this study was to compare the 
treatment effect of pioglitazone and metformin on fatty liver. 
Materials and methods: This double blinded clinical trial study was performed in 2012 
among patients referring to gastrointestinal clinics in the city of Ilam. 105 non-alcoholic fatty 
liver patients were selected and participated in this study. Patients were randomly divided 
into two groups of metformin and pioglitazone. Using double blinded clinical trial, one group 
was treated by pioglitazone (30 mg daily) and the other by metformin (500 mg daily) both for 
3 months. Then using sonography, the severity of fatty liver was compared in the two groups. 
Results: Multivariable logistic regression showed that there was no significant difference 
between the effect of pioglitazone and metformin on the treatment of fatty liver (p=0.92). 
There was a significant difference between severity of fatty liver and BMI before treatment 
(p<0.004) but it was not confirmed after the treatment. There was also a significant difference 
between the severity of fatty liver and gender before treatment (p<0.003) but it was not 
confirmed after treatment. There was a negative significant relationship between age and the 
treatment effect of metformin but not in the pioglitazone group.  
Conclusions: Both pioglitazone and metformin had a notable effect on the treatment of fatty 
liver solely while there was no significant difference between their effectiveness. The 
effectiveness of metformin was higher among males compared to that of pioglitazone.  
 Keywords: Fatty liver, NAFLD, pioglitazone, metformin,   
Introduction 
Non-alcoholic fatty liver (NAFLD) is one 
of the most prevalent digestive diseases in 
the world, particularly among obese 
people, and its prevalence is increasing 
rapidly. Its prevalence ranged from 25-
70% among different countries (1-3). 
NAFLD can proceed to a non-alcoholic 
hepatitis and finally result in cirrhosis or 
even hepatocellular carcinoma. The 
prevalence of cirrhosis in NAFLD has 
been reported up to 25% (4-7). Prevention 
and control of fatty liver is important at the 
primary stages. Different studies have 
reported that metformin can cause insulin 
sensitivity by reduction of 
gluconeogenesis and intervention in the 
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consumption and reabsorption of glucose; 
however, pioglitazone causes a distribution 
of the fat from muscle and liver to the fat 
tissue and therefore affects the sensitivity 
of insulin in liver and skeletal muscles (8). 
There is an insulin resistance among 
patients with NAFLD and metformin and 
pioglitazone are two different classes of 
drugs that affect insulin sensitivity. They 
also have a considerable effect on the 
disease; therefore, the current study was 
triggered to compare the effectiveness of 
the two above-mentioned drugs among 
patients with confirmed fatty liver in the 
city of Ilam.         
Materials and methods  
Among patients referring to 
gastrointestinal clinics in the city of Ilam, 
105 patients diagnosed with confirmed 
NAFLD were selected and participated in 
this study. They were randomly divided 
into two groups of pioglitazone (53 
participants) and metformin (52 
participants). Excluding criteria were: 
patients with alcohol consumption, 
Cushing syndrome, Cirrhosis, patients 
with renal failure, heart failure, and those 
with intolerability of metformin or 
pioglitazone. Using double blind clinical 
trial, one group was treated by 
pioglitazone (30 mg daily) and another 
group by metformin (500mg daily) both 
for 3 months. At first, sonography was 
applied for each patient at the start of 
study.  After 3 months, the severity of fatty 
liver (mild, moderate, severe) was 
evaluated by comparison of new and 
primary sonography. Finally, the results of 
metformin and pioglitazone groups were 
compared for any significant differences. 
Results  
Among 105 participants, 57.1% were 
males aging 15 to 50 years old. 46 patients 
(44%) were in age group of 36-45 yrs and 
4 patients (4%), were in age group of 15-
25 years. The weight of participants 
ranged from 60-80 kg from whom 56 
patients (53%) were over 70kg. 56% of 
patients had a normal BMI (18.5-24.5), 
40% were overweight (BMI= 25-29.5) and 
3% were obese (BMI>30). 
Three patients (2.9%) had concurrent 
diseases such as diabetes or 
cholesterolemia and 2.9% of participants 
had a medication history such as oral 
contraceptive while others (97.1%) had no 
medication history . 
According to the biopsy and sonography 
reports, most patients had a mild to 
moderate fatty liver and only 17.1% had a 
severe fatty liver. The results of control 
sonography (after treatment) showed that 
94.3% of patients had a mild to moderate 
fatty liver and only 5.7% had severe fatty 
liver which indicated a positive effect of 
metformin and pioglitazone on fatty liver 
disease. 
There was not a significant difference 
between age and the severity of fatty liver 
before or after the treatment (p>0.05). 
There was a significant difference between 
the severity of fatty liver and BMI before 
treatment (p<0.004), but it was not 
confirmed after the treatment (p=0.64). 
There was a positive relationship between 
BMI and moderate to severe fatty liver. 
There was also a significant difference 
between the severity of fatty liver and 
gender before the treatment (p<0.003) but 
it was not confirmed after the treatment 
(p=0.18). The moderate and severe fatty 
liver was more frequent among males and 
the mild fatty liver was equally prevalent 
in both genders (Table1). 
Before treatment with metformin, 15 
patients (28.9%) had mild fatty liver, 30 
patients (57.7%) moderate fatty liver and 7 
patients (13.5%) severe fatty liver; 
however, these figures changed to 36 
(69.2%) mild, 14 (26.9%) moderate and 2 
(3.9%) severe fatty liver, respectively 
indicating the considerable effect of 
metformin on the fatty liver. 
Before treatment with pioglitazone, 9 
patients (17%) had mild, 33 patients 
(62.3%) moderate and 11 patients (20.8%) 
severe fatty liver; however, these figures 
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changed to 28 (54.7%.) mild, 20 (37.7%) 
moderate and 4 (7.6%) severe fatty liver, 
respectively indicating the positive effect 
of pioglitazone on the fatty liver (Tables 2- 
4). 
Table 1. Distribution of patients with fatty liver based on their gender and type of medication. 
Severity of fatty liver 
Drug of 
used 
Total Gender 
P 
Male  Female 
N  % 
N  % N  % 
Before 
treatment 
Mild 
Metformin 62.5 15 45.8 11 16.7 4 
P=0.003 
df=1 
X
2
=8.7 
 
 
Pioglitazone 37.5 9 4.2 1 33.3 8 
Total 100 24 50 12 50 12 
Moderate 
Metformin 47.6 30 20.6 13 27 17 
Pioglitazone 52.4 33 22.2 14 30.2 19 
Total 100 63 42.9 27 57.1 36 
Severe 
Metformin 38.9 7 22.2 4 16.7 3 
Pioglitazone 61.1 11 1.1 2 50 9 
Total 100 18 33.3 6 66.7 12 
After 
treatment 
Mild 
Metformin 55.4 36 26.2 17 29.2 19 
 
P=0.18 
df=1 
X
2
=1.8 
 
Pioglitazone 44.6 29 13.8 9 30.8 20 
Total 100 65 40 26 60 39 
Moderate 
Metformin 41.2 14 29.4 10 11.8 4 
Pioglitazone 58.8 20 23.5 8 35.3 12 
Total 100 34 52.9 18 47.1 16 
Severe 
Metformin 33.3 2 16.7 1 16.7 1 
Pioglitazone 66.7 2 0 0 66.7 4 
Total 100 6 16.7 1 83.3 5 
 
 
Table 2. Comparison between the severity of fatty liver before and after treatment with metformin and 
pioglitazone.  
Total 
Severity of fatty liver after treatment 
Severity of fatty liver before treatment 
Severe Moderate Mild 
% N % N % N % N % N  
28.8 15 0 0 0 0 28.8 15 62.5 15 Mild  
 
Metformin 
 
57.7 30 0 0 21.2 11 36.5 19 47.6 30 Moderate 
13.5 7 3.8 2 5.8 3 3.8 2 38.9 7 Severe 
100 52 3.8 2 26.9 14 69.2 36 100 52 Total 
17 9 0 0 0 0 17 9 37.5 9 Mild  
pioglitazone 
 
 
62.3 33 0 0 28.3 15 34 18 52.4 33 Moderate 
20.8 11 7.5 4 9.4 5 3.8 2 61.1 11 Severe 
100 53 7.5 4 37.7 20 54.7 29 100 53 Total 
 
After disregarding of some confounding 
variables such as age, gender and BMI, the 
results of multivariable logistic regression 
showed that there was no significant 
difference between the effect of 
pioglitazone and metformin on the 
treatment of fatty liver (Table 4).  
There was a significant relationship 
between gender and the type of treatment 
(p<0.02). The group of metformin 
included 46.2% males and the group of 
pioglitazone included 67.9% males.  
Regarding BMI, there was no significant 
difference between 2 groups of treatment; 
however, the mean age of participants in 
the metformin group was 3.5 years higher 
than those in the pioglitazone group. There 
was a negative significant relationship 
between age and the rate of improvement 
in the metformin group, but not in the 
pioglitazone group (Table 4). 
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Table 3. The frequency of betterment rate among patients with fatty liver based ontheir medication.  
Total 
 
Betterment rate 
Type of medication 
Untreated Relatively 
treated 
Completely 
treated 
% N % N % N % N 
100 52 53.8 28 42.3 22 3.8 2 Metformin 
100 53 52.8 28 43.4 23 3.8 2 pioglitazone 
100 105 53.3 56 42.9 45 3.8 4 Total 
 
Table 4.  The relationship between the effect of age and BMI on the betterment of fatty liver based on the 
treatments.   
P OR 
df Wald 
Standard 
deviation 
B coefficient Variable Treatment Upper 
limit 
Lower 
limit 
0.037 0.995 0.862 1 4.35 0.037 0.077 Age  
Metformin 0.54 1.21 0.693 1 0.373 0.143 -0.087 BMI 
0.17 - - 1 1.80 3.84 5.17 Constant rate 
0.28 1.13 0.965 1 1.16 0.041 0.044 Age  
Pioglitazone 
 
0.15 1.70 0.918 1 2.01 0.15 0.22 BMI 
0.057 - - 1 3.63 3.84 -7.33 Constant rate 
 
Both McNamara and binomial tests 
showed that either metformin or 
pioglitazone had a significant effect on the 
treatment of fatty liver alone (p<0.0001). 
Discussion 
Metformin is attributed to biguanide drugs 
cluster and pioglitazone is attributed to 
thiazolidinedione drugs cluster. These 2 
medications are used widely for diabetic 
diseases. The conception of using these 
drugs for NAFLD was triggered during the 
past decade. 
The current study investigated 105 patients 
with fatty liver attending to 
gastroenterology clinics in the city of Ilam 
and their fatty liver was confirmed as mild, 
moderate and severe on the basis of 
sonography reports. The other methods for 
diagnosis of fatty liver are biopsy, CT 
scan, and MRI. Sonography is a preferred 
method since other methods of diagnosis 
are invasive or expensive and may be 
accompanied by some side effects.     
Both metformin and pioglitazone had a 
significant effect on the treatment of fatty 
liver lonely and there was no significant 
difference between the effectiveness of 
these drugs in the treatment of fatty liver. 
No similar study had been carried out in 
Iran to investigate the effects of metformin 
or pioglitazone on fatty liver. However, 
some international studies have compared 
the effect of metformin or pioglitazone and 
placebo in a limited way for this purpose. 
Most studies have reported the 
effectiveness of both metformin and 
pioglitazone on fatty liver in comparison to 
placebo (9).  In the current study, both 
McNamara and Binomial tests showed that 
either metformin or pioglitazone had a 
significant effect on the treatment of fatty 
liver alone. 
Belfort et al studied the effect of 
pioglitazone accompanied with low fat 
regiment among patients with fatty liver 
and compared them with placebo and 
finally reported a significant improvement 
in the treatment group compared with 
placebo (9). The result of that study was 
consistent with what was obtained in the 
current study.       
Another study by Nair et al. reported that 
applying metformin, accompanied with a 
usual nutritional regiment, among patients 
with fatty liver for 12 months caused a 
reduction in hepatic enzymes and 
hepatocellular inflammation (10).  The 
result of that study was in line with our 
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study. Some more studies have applied 
metformin or pioglitazone among patients 
suffering from fatty liver with some minor 
methodological variations such as 
limitations of lipid intake, using vitamin E, 
duration of the project study and all of 
them supported the positive effects of 
these drugs on improving fatty liver (11-
21).  The current study was the first 
research to compare the effects of these 2 
drugs among fatty liver patients which 
revealed that both drugs were suitable for 
this purpose. However, metformin was 
more effective than pioglitazone in the 
treatment of fatty liver among males.  
Conclusion 
There was a negatively significant 
relationship between age and improvement 
speed in the metformin group but not in 
the pioglitazone group. Both metformin 
and pioglitazone had a significant effect on 
the treatment of fatty liver alone and there 
was no significant difference between the 
effectiveness of these drugs in the 
treatment of fatty liver. Also, metformin 
was more effective than pioglitazone in the 
treatment of fatty liver among males.   
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